These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 14978663

  • 1. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
    Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Wong WK.
    Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
    [Abstract] [Full Text] [Related]

  • 2. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
    Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR.
    Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
    [Abstract] [Full Text] [Related]

  • 3. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Seibold JR.
    Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
    [Abstract] [Full Text] [Related]

  • 4. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
    Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.
    Ann Rheum Dis; 2006 Oct; 65(10):1325-9. PubMed ID: 16540546
    [Abstract] [Full Text] [Related]

  • 5. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J.
    Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
    [Abstract] [Full Text] [Related]

  • 6. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [Abstract] [Full Text] [Related]

  • 7. D-penicillamine is not an effective treatment in systemic sclerosis.
    Furst DE, Clements PJ.
    Scand J Rheumatol; 2001 Nov; 30(4):189-91. PubMed ID: 11578010
    [Abstract] [Full Text] [Related]

  • 8. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE.
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [Abstract] [Full Text] [Related]

  • 9. D-penicillamine in systemic sclerosis? Yes!
    Medsger TA, Lucas M, Wildy KS, Baker C.
    Scand J Rheumatol; 2001 Jun; 30(4):192-4. PubMed ID: 11578011
    [Abstract] [Full Text] [Related]

  • 10. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
    Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA, Steen VD, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Furst DE.
    Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
    [Abstract] [Full Text] [Related]

  • 11. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
    Sultan N, Pope JE, Clements PJ, Scleroderma Trials Study Group.
    Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
    [Abstract] [Full Text] [Related]

  • 12. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
    Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D, Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials.
    Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
    [Abstract] [Full Text] [Related]

  • 13. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial.
    Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White B, Weisman M, Barr W, Moreland L, Martin R, Medsger TA, Steen V, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Peter JB, Seibold JR.
    Rheumatology (Oxford); 2001 Jun; 40(6):615-22. PubMed ID: 11426017
    [Abstract] [Full Text] [Related]

  • 14. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA, Seibold JR, Relaxin Study Group, Scleroderma Clinical Trials Consortium.
    J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
    [Abstract] [Full Text] [Related]

  • 15. Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    Strand V.
    Arthritis Rheum; 2002 Nov; 46(11):2836-7. PubMed ID: 12428222
    [No Abstract] [Full Text] [Related]

  • 16. Penicillamine in the treatment of systemic sclerosis.
    Clements PJ.
    Curr Rheumatol Rep; 1999 Oct; 1(1):38-42. PubMed ID: 11123013
    [Abstract] [Full Text] [Related]

  • 17. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.
    Steen VD, Medsger TA, Rodnan GP.
    Ann Intern Med; 1982 Nov; 97(5):652-9. PubMed ID: 7137731
    [Abstract] [Full Text] [Related]

  • 18. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset.
    Derk CT, Huaman G, Jimenez SA.
    Br J Dermatol; 2008 May; 158(5):1063-8. PubMed ID: 18284395
    [Abstract] [Full Text] [Related]

  • 19. Dermal elastin and collagen in systemic sclerosis. Effect of D-penicillamine treatment.
    Pasquali Ronchetti I, Guerra D, Quaglino D, Vincenzi D, Manzini E, Canossi B, Manzini CU.
    Clin Exp Rheumatol; 1989 May; 7(4):373-83. PubMed ID: 2591110
    [Abstract] [Full Text] [Related]

  • 20. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
    Mayes MD, O'Donnell D, Rothfield NF, Csuka ME.
    Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.